Free Trial
NASDAQ:ELDN

Eledon Pharmaceuticals Q1 2025 Earnings Report

Eledon Pharmaceuticals logo
$2.59 +0.02 (+0.78%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$2.60 +0.01 (+0.39%)
As of 08/29/2025 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eledon Pharmaceuticals EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.28
Beat/Miss
Beat by +$0.20
One Year Ago EPS
N/A

Eledon Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eledon Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Eledon Pharmaceuticals' Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Eledon Pharmaceuticals Earnings Headlines

Craig-Hallum Remains a Buy on Eledon Pharmaceuticals (ELDN)
Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why
Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.tc pixel
Eledon Posts Narrower Loss in Q2
See More Eledon Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eledon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eledon Pharmaceuticals and other key companies, straight to your email.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals (NASDAQ:ELDN) operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

View Eledon Pharmaceuticals Profile

More Earnings Resources from MarketBeat